Last Updated : May 1, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | N/A | Complete | ||
| Omnitrope | Somatropin (rDNA origin) | Growth hormone deficiency in children and adults | N/A | Complete | ||
| Vyvanse | Lisdexamfetamine dimesylate | Attention deficit hyperactivity disorder | Do not list | Complete | ||
| Levemir | Insulin detemir | Diabetes mellitus Type1, Pediatrics | Do not list | Complete | ||
| Azarga | Brinzolamide and timolol maleate suspension | Glaucoma and ocular hypertension | List in a similar manner to other drugs in class | Complete | ||
| Simponi | Golimumab | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
| Cimzia | Certolizumab pegol | Arthritis, rheumatoid | Do not list | Complete | ||
| Soliris | Eculizumab | Paroxysmal nocturnal hemoglobinuria (PNH) | Do not list | Complete | ||
| Multaq | Dronedarone hydrochloride | Atrial fibrillation | Do not list | Complete | ||
| Nplate | Romiplostim | Chronic immune (idiopathic) thrombocytopenic purpura (ITP) | Do not list | Complete |
Last Updated : May 1, 2024